PSMA PET/CT imaging is changing the way prostate cancer is detected, staged, and managed. By providing more detailed information about where cancer may be located, this advanced imaging technology can help physicians make more informed treatment decisions and offer patients a clearer understanding of their disease.
Today, Dr. Garrett Pohlman welcomes two experts with complementary perspectives: Dr. Gregory McMahon, a board-certified urologist with Mid-Atlantic Urology in Pennsylvania who completed his urologic oncology fellowship at Yale University, and Dr. Umesh Oza, a nuclear radiologist practicing in Dallas, Texas, who completed his nuclear medicine fellowship at Harvard.
Together, they explain how PSMA PET/CT differs from conventional imaging, when it may be appropriate for patients with prostate cancer, and how its findings can influence individualized treatment planning. They also explore the importance of communication between urologists and radiologists, the challenges of interpreting uncertain findings, and the role of different radioactive isotopes in PET imaging.
This episode is the first in a multi-episode educational series on PSMA PET/CT in partnership with Telix Pharmaceuticals. Stay tuned to learn how this technology is reshaping prostate cancer care and why understanding your imaging options matters.
Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation.
Show Highlights:
- Understanding PSMA PET/CT and the combination of molecular imaging with conventional CT technology
- The advantages of PSMA PET/CT for detecting prostate cancer at lower PSA levels
- Three common clinical scenarios in which PSMA PET/CT may be recommended
- The role of PSA levels, Gleason scores, and prostate cancer risk groups in imaging decisions
- Key findings from the proPSMA study comparing PSMA PET/CT with conventional imaging
- Using imaging results to develop more individualized prostate cancer treatment plans
- The challenges of interpreting uncertain rib and bone lesions
- Differences between gallium-68 and fluorine-18 in PSMA PET/CT imaging
- Essential clinical information radiologists need to interpret scans accurately
- Real-world examples of PSMA PET/CT findings influencing treatment recommendations
- The importance of continued research and clinical trials as imaging technology advances
- Questions patients can ask their healthcare providers about PSMA PET/CT imaging
Links:
- Follow Dr. Pohlman on Twitter and Instagram – @gpohlmanmd
- Get your free What To Expect Guide (or find the link on our podcast website)
- Join our Facebook group
- Follow Dr. Pohlman on Twitter and Instagram
- Sign up for the Prostate Health Academy to access Dr. Pohlman’s free mini-webinar, where he shares his top three tips for promoting men’s prostate health, longevity, and quality of life.
- Telix Pharmaceuticals
Recent Comments